EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 47 filers reported holding EDGEWISE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $704,371 | +5.9% | 39,110 | +7.2% | 0.00% | 0.0% |
| Q1 2024 | $665,158 | +105.3% | 36,467 | +23.1% | 0.00% | – |
| Q4 2023 | $324,043 | +499.0% | 29,620 | +213.7% | 0.00% | – |
| Q3 2023 | $54,097 | -51.0% | 9,441 | -33.7% | 0.00% | – |
| Q2 2023 | $110,306 | +17.4% | 14,233 | +1.0% | 0.00% | – |
| Q1 2023 | $93,994 | -30.5% | 14,092 | -6.9% | 0.00% | – |
| Q4 2022 | $135,280 | +17.6% | 15,132 | +29.0% | 0.00% | – |
| Q3 2022 | $115,000 | +13.9% | 11,733 | -7.7% | 0.00% | – |
| Q2 2022 | $101,000 | -37.3% | 12,712 | -23.5% | 0.00% | – |
| Q1 2022 | $161,000 | -50.0% | 16,617 | -21.3% | 0.00% | – |
| Q4 2021 | $322,000 | +192.7% | 21,104 | +218.6% | 0.00% | – |
| Q3 2021 | $110,000 | -69.7% | 6,624 | -61.1% | 0.00% | – |
| Q2 2021 | $363,000 | – | 17,031 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |